Winolap Nasal Spray
Olopatadine 0.6% Nasal prep
120 MDI
Sun Pharmaceutical Industries Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Winolap Nasal Spray is used for:
Allergic rhinitis
Adult Dose
Nasal
Seasonal allergic rhinitis
Adult: As 0.6% spray: 2 sprays into each nostril bid.
Child: 6-11 yr 1 spray into each nostril bid.
Child Dose
Nasal
Seasonal Allergic Rhinitis
<6 years: Safety and efficacy not established
6-12 years: 1 spray each nostril twice daily.
>12 years: 2 sprays each nostril twice daily.
Renal Dose
Administration
Priming: Before initial use, prime Nasal Spray by releasing 5 sprays or until a fine mist appears. When Nasal Spray has not been used for more than 7 days, re-prime by releasing 2 sprays.
Contra Indications
It is contraindicated incase of hypersensitivity to Olopatadine or to any component of the preparation.
Precautions
Patients should be informed to avoid spraying Nasal Spray in their eyes. Patient w/ other nasal disease. Patient Counselling May impair ability to engage in activities requiring complete mental alertness and motor coordination (e.g. driving or operating machinery) after admin of the nasal spray. Nasal examinations should be performed periodically for signs of adverse effects on the nasal mucosa.
Lactation: Unknown whether distributed in breast milk, caution advised
Pregnancy-Lactation
Interactions
May result in additive CNS depression w/ CNS depressants.
Adverse Effects
Side effects of Olopatadine 0.6% Nasal prep :
>10%
Bitter taste (12.8%; 1% pediatric),Respiratory epistaxis (3-25%)
1-10%
Headache (4.4%),Depression (2%),Fatigue (1%),Somnolence (1%),Weight gain (1%),Epistaxis (3.2%; 5.7% pediatric),Upper respiratory tract infection (2.6% pediatric),Pharyngolaryngeal pain (2.2%),Postnasal drip (1.5%),Cough (1.4%),Urinary tract infection (1.2%),Upper respiratory tract infection in children (3%)
<1%
CPK elevation,Dry mouth,Anosmia,Hyposmia,Nasopharyngitis,Throat irritation,Influenza
Mechanism of Action
Olopatadine is a relatively selective histamine H1-receptor antagonist which inhibits the release of histamine from mast cells and histamine-induced effects on conjunctival epithelial cells. It shares many of the pharmacologic effects of mast cell stabilisers.
Note
Winolap 120 MDI Nasal Spray manufactured by Sun Pharmaceutical Industries Ltd.. Its generic name is Olopatadine 0.6% Nasal prep. Winolap is availble in Nepal.
Farmaco Nepal drug index information on Winolap Nasal Spray is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.